Unternehmen
Eli Lilly and Company

Aktueller Kurs
190.77 USD

Symbol
LLY

ISIN
US5324571083

Börse
NYSE

Sektor
Health Care

Marktkapitalisierung
182.487 Mrd. US

Branche
Pharmaceuticals

Dividendenrendite
1.78 %

Ausschüttungsquote
44.43 %

KGV
31.21

KUV (TTM)
6.54

KGVe
20.58

Kursziel
185.88 USD

Unternehmen
Eli Lilly and Company

Aktueller Kurs
190.77 USD

Symbol
LLY

ISIN
US5324571083

Börse
NYSE

Marktkapitalisierung
182.487 Mrd. USD

Sektor
Health Care

Branche
Pharmaceuticals

Dividendenrendite
1.78 %

Ausschüttungsquote
44.43 %

KGV
31.21

KUV (TTM)
6.54

KGVe
20.58

Kursziel
185.88 USD

Live-Chart (verzögert)

Firmenbeschreibung

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company Fundamentaldaten

Jahre und Quartale beziehen sich jeweils auf das Geschäftsjahr des Unternehmens. (Das Geschäftsjahr kann ggf. vom Kalenderjahr abweichen.)

Das Geschäftsjahr von Eli Lilly and Company endet im Dezember.

Gewinn pro Jahr & Quartal (Net Income) in Mrd. USD

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.000 0.000 0.000 0.000 0.000
2020 1.457 1.412 1.208 0.000 4.077
2019 4.242 1.327 1.254 1.496 8.318
2018 1.217 -0.260 1.150 1.125 3.232
2017 -0.111 1.008 0.556 -1.657 -0.204
2016 0.440 0.748 0.778 0.772 2.738
2015 0.530 0.601 0.800 0.478 2.408
2014 0.728 0.734 0.501 0.429 2.391
2013 1.548 1.206 1.203 0.728 4.685
2012 1.011 0.924 1.327 0.827 4.089
2011 1.056 1.197 1.236 0.858 4.348
2010 1.248 1.349 1.303 1.170 5.070

Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 1.75 1.89 1.54 0 5.18
2019 1.33 1.5 1.48 1.73 6.04
2018 1.34 1.5 1.39 1.33 5.56
2017 0.98 1.11 1.05 1.14 4.28
2016 0.83 0.86 0.88 0.95 3.52
2015 0.87 0.9 0.89 0.78 3.44
2014 0.7 0.68 0.66 0.75 2.79
2013 1.14 1.16 1.11 0.74 4.15
2012 0.92 0.83 0.79 0.85 3.39
2011 1.24 1.18 1.13 0.87 4.42
2010 1.18 1.24 1.21 1.11 4.74

Umsatz pro Jahr & Quartal in Mrd. USD

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 5.8598 5.4994 5.7406 0 17.0998
2019 5.0922 5.6367 5.4766 6.114 22.3195
2018 5.7 6.3552 6.0619 6.4386 24.5557
2017 5.2283 5.8243 5.658 6.1607 22.8713
2016 4.8651 5.4048 5.1917 5.7605 21.2221
2015 4.6447 4.9787 4.9597 5.3756 19.9587
2014 4.6831 4.9356 4.8756 5.1213 19.6156
2013 5.602 5.9297 5.7726 5.8088 23.1131
2012 5.602 5.6007 5.4433 5.9574 22.6034
2011 5.8392 6.2528 6.1479 6.0466 24.2865
2010 5.4855 5.7487 5.6548 6.187 23.076

Umsatz je Aktie pro Jahr & Quartal

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 6.43 6.04 6.30 0.00 22.21
2019 5.18 6.09 5.96 6.53 23.85
2018 5.43 6.17 5.91 6.23 23.75
2017 4.95 5.51 5.36 5.86 21.74
2016 4.58 5.10 4.89 5.42 19.98
2015 4.35 4.67 4.66 5.04 18.72
2014 4.35 4.59 4.54 4.77 18.26
2013 5.13 5.47 5.33 5.35 21.30
2012 5.05 5.01 4.86 5.33 20.24
2011 5.25 5.61 5.52 5.43 21.80
2010 4.97 5.21 5.12 5.59 20.86

Gewinn-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 -100.00
2020 -2.62 -3.06 -14.42 -100.00 -50.99
2019 277.03 -68.71 -5.52 19.28 157.38
2018 0.00 -121.35 0.00 -2.13 0.00
2017 -114.36 0.00 -44.88 -398.22 -107.46
2016 -8.01 69.89 4.05 -0.80 13.67
2015 23.57 13.47 33.11 -40.18 0.75
2014 0.05 0.77 -31.75 -14.40 -48.97
2013 87.11 -22.08 -0.26 -39.53 14.58
2012 17.82 -8.65 43.63 -37.64 -5.96
2011 -9.72 13.39 3.26 -30.58 -14.24
2010 36.34 8.08 -3.41 -10.23 17.11

Umsatz-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 -4.16 -6.15 4.39 0.00 0.00
2019 -20.91 10.69 -2.84 11.64 -9.11
2018 -7.48 11.49 -4.62 6.21 7.36
2017 -9.24 11.40 -2.86 8.88 7.77
2016 -9.50 11.09 -3.94 10.96 6.33
2015 -9.31 7.19 -0.38 8.39 1.75
2014 -19.38 5.39 -1.22 5.04 -15.13
2013 -5.97 5.85 -2.65 0.63 2.25
2012 -7.35 -0.02 -2.81 9.44 -6.93
2011 -5.62 7.08 -1.68 -1.65 5.25
2010 -7.56 4.80 -1.63 9.41 5.68

Eli Lilly and Company Fundamentaldaten

Gewinn pro Jahr & Quartal (Net Income)

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.000 0.000 0.000 0.000 0.000
2020 1.457 1.412 1.208 0.000 4.077
2019 4.242 1.327 1.254 1.496 8.318
2018 1.217 -0.260 1.150 1.125 3.232
2017 -0.111 1.008 0.556 -1.657 -0.204
2016 0.440 0.748 0.778 0.772 2.738
2015 0.530 0.601 0.800 0.478 2.408
2014 0.728 0.734 0.501 0.429 2.391
2013 1.548 1.206 1.203 0.728 4.685
2012 1.011 0.924 1.327 0.827 4.089
2011 1.056 1.197 1.236 0.858 4.348
2010 1.248 1.349 1.303 1.170 5.070

Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 1.75 1.89 1.54 0 5.18
2019 1.33 1.5 1.48 1.73 6.04
2018 1.34 1.5 1.39 1.33 5.56
2017 0.98 1.11 1.05 1.14 4.28
2016 0.83 0.86 0.88 0.95 3.52
2015 0.87 0.9 0.89 0.78 3.44
2014 0.7 0.68 0.66 0.75 2.79
2013 1.14 1.16 1.11 0.74 4.15
2012 0.92 0.83 0.79 0.85 3.39
2011 1.24 1.18 1.13 0.87 4.42
2010 1.18 1.24 1.21 1.11 4.74

Umsatz pro Jahr & Quartal

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0 0 0 0 0
2020 5.8598 5.4994 5.7406 0 17.0998
2019 5.0922 5.6367 5.4766 6.114 22.3195
2018 5.7 6.3552 6.0619 6.4386 24.5557
2017 5.2283 5.8243 5.658 6.1607 22.8713
2016 4.8651 5.4048 5.1917 5.7605 21.2221
2015 4.6447 4.9787 4.9597 5.3756 19.9587
2014 4.6831 4.9356 4.8756 5.1213 19.6156
2013 5.602 5.9297 5.7726 5.8088 23.1131
2012 5.602 5.6007 5.4433 5.9574 22.6034
2011 5.8392 6.2528 6.1479 6.0466 24.2865
2010 5.4855 5.7487 5.6548 6.187 23.076

Umsatz je Aktie pro Jahr & Quartal

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 6.43 6.04 6.30 0.00 22.21
2019 5.18 6.09 5.96 6.53 23.85
2018 5.43 6.17 5.91 6.23 23.75
2017 4.95 5.51 5.36 5.86 21.74
2016 4.58 5.10 4.89 5.42 19.98
2015 4.35 4.67 4.66 5.04 18.72
2014 4.35 4.59 4.54 4.77 18.26
2013 5.13 5.47 5.33 5.35 21.30
2012 5.05 5.01 4.86 5.33 20.24
2011 5.25 5.61 5.52 5.43 21.80
2010 4.97 5.21 5.12 5.59 20.86

Gewinn-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 -100.00
2020 -2.62 -3.06 -14.42 -100.00 -50.99
2019 277.03 -68.71 -5.52 19.28 157.38
2018 0.00 -121.35 0.00 -2.13 0.00
2017 -114.36 0.00 -44.88 -398.22 -107.46
2016 -8.01 69.89 4.05 -0.80 13.67
2015 23.57 13.47 33.11 -40.18 0.75
2014 0.05 0.77 -31.75 -14.40 -48.97
2013 87.11 -22.08 -0.26 -39.53 14.58
2012 17.82 -8.65 43.63 -37.64 -5.96
2011 -9.72 13.39 3.26 -30.58 -14.24
2010 36.34 8.08 -3.41 -10.23 17.11

Umsatz-Wachstum in Prozent

Q1
Jan-Mrz
Q2
Apr-Jun
Q3
Jul-Sep
Q4
Okt-Dez
Jahr
Jan-Dez
2021 0.00 0.00 0.00 0.00 0.00
2020 -4.16 -6.15 4.39 0.00 0.00
2019 -20.91 10.69 -2.84 11.64 -9.11
2018 -7.48 11.49 -4.62 6.21 7.36
2017 -9.24 11.40 -2.86 8.88 7.77
2016 -9.50 11.09 -3.94 10.96 6.33
2015 -9.31 7.19 -0.38 8.39 1.75
2014 -19.38 5.39 -1.22 5.04 -15.13
2013 -5.97 5.85 -2.65 0.63 2.25
2012 -7.35 -0.02 -2.81 9.44 -6.93
2011 -5.62 7.08 -1.68 -1.65 5.25
2010 -7.56 4.80 -1.63 9.41 5.68

Eli Lilly and Company Dividenden-Entwicklung

Ex-Tag Record Date Zahltag Dividende
2021-02-11 2021-02-12 2021-03-10 0.85
2020-11-12 2020-11-13 2020-12-10 0.74
2020-08-13 2020-08-14 2020-09-10 0.74
2020-05-14 2020-05-15 2020-06-10 0.74
2020-02-13 2020-02-14 2020-03-10 0.74
2019-11-14 2019-11-15 2019-12-10 0.645
2019-08-14 2019-08-15 2019-09-10 0.645
2019-05-16 2019-05-17 2019-06-10 0.645
2019-02-14 2019-02-15 2019-03-08 0.645
2018-11-14 2018-11-15 2018-12-10 0.5625
2018-08-14 2018-08-15 2018-09-10 0.5625
2018-05-16 2018-05-17 2018-06-08 0.5625
2018-02-14 2018-02-15 2018-03-09 0.5625
2017-11-14 2017-11-15 2017-12-08 0.52
2017-08-11 2017-08-15 2017-09-08 0.52
2017-05-11 2017-05-15 2017-06-09 0.52
2017-02-13 2017-02-15 2017-03-10 0.52
2016-11-10 2016-11-15 2016-12-09 0.51
2016-08-11 2016-08-15 2016-09-09 0.51
2016-05-11 2016-05-13 2016-06-10 0.51